Nearly a quarter of its value lost in one month: DBV Technologies stock plummets

A stock below its three moving averages, near its support level at €1.77

The DBV Technologies stock is declining 1.98% to €1.74, after falling 13.97% over the week. The price is below its 20-day moving average (gap of -16.54%), its 50-day moving average and its 200-day moving average, the latter standing at €3.07. The stock has fallen below its support level of €1.77, and the RSI at 29 reflects the accumulated selling pressure over recent weeks.

Over three months, the decline reaches 37.46%, and the stock ranks at the bottom of the index table, behind a very large majority of its members. The rebound observed yesterday following a long series of declines therefore did not hold.

Four funds cumulatively hold 4% of capital sold short, up over one month

On the short-selling side, pressure is not weakening: four funds collectively hold 4% of the capital in a short position, according to available disclosures, compared to 3.74% thirty days ago. The increase remains modest, at +0.26 percentage points, but the level is elevated for a stock of this size. This positioning coincides with a period of marked pressure on the stock, as the filing of the license application with the FDA for the peanut allergy patch was announced at the end of September.

When publishing the first half of 2026 results on July 16, the company stated it could finance its activities through the third quarter of 2027. The analysts' views remain to be monitored on the stock, which is listed on Euronext Paris and on the Nasdaq (1 ADS for 5 ordinary shares).